Curaleaf Counters Aurora's Circular with Details on $398M Dilution and Cash Burn
CURLF sits 86% above its 52-week low of $5.4.
Summary
Curaleaf issued a point-by-point rebuttal to Aurora's Directors' Circular, detailing Aurora's $398M in dilutive equity raises, negative operating cash flow, and declining guidance, while reaffirming its US$4.00 per share offer as the best path for Aurora shareholders.
Key Events · M&A and Partnerships · CURLF
-
Curaleaf Rebuts Aurora's Directors' Circular
Curaleaf issued a detailed response to Aurora's Directors' Circular, reaffirming its US$4.00 per share hostile takeover offer and arguing it represents a 45% premium to Aurora's unaffected trading price.
-
Aurora's $398M Dilution Exposed
Curaleaf claims Aurora has raised approximately US$398 million through dilutive equity issuances since September 2020, diluting shareholders by approximately 31%, with additional dilution ongoing through its ATM program.
-
Aurora's Cash Burn and Declining Guidance
Curaleaf states Aurora's operating cash flow was negative C$4.4 million in the June quarter, and that Aurora's own guidance calls for fiscal 2027 revenue to decline toward fiscal 2025 levels with adjusted EBITDA significantly below fiscal 2026.
-
Curaleaf's Superior Fundamentals Highlighted
Curaleaf generated US$50 million in operating cash flow and US$17 million in free cash flow in H1 2026, with US$145 million LTM operating cash flow, and successfully raised US$500 million in senior secured notes.
Analysis · CURLF · Life Sciences
The latest salvo in the hostile takeover battle adds concrete new ammunition: Aurora has raised US$398 million through dilutive equity issuances since September 2020, diluting shareholders by roughly 31%, and its Board sold shares through the ATM program at US$3.57 and US$3.09 — well below the US$4.00 offer. Curaleaf also counters Aurora's 'debt-free' narrative by pointing to negative C$4.4 million operating cash flow in the June quarter and management's own guidance for declining fiscal 2027 revenue and EBITDA. The filing reinforces Curaleaf's case that its 45% premium offer is the best path for Aurora shareholders, while highlighting Curaleaf's superior cash generation (US$145 million LTM operating cash flow) and institutional debt access.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.6% of the 1872 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $10.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.